Vaccines Supply Chain

LNP and Lipid Suppliers

Who can actually mix a commercial LNP. IP, lipids, and sponsor in-house mixing. Not a liter ranking.

NodeRoleWho uses itConstraint
Acuitas (private)LNP IP / licensesPfizer/BioNTech Comirnaty historically; other mRNA licensesIP, not a public equity in this roster.
CordenPharmaLipid manufacturingCommercial mRNA lipidsSame peptide/lipid expansion story as GLP-1, different molecule.
Sponsor in-houseLNP mixing and fillModerna, BioNTech (plus CureVac assets), PfizerThe mixing step is a trade secret as much as a plant.
LonzamRNA DS and LNP CDMOWhen sponsors do not run every stepShared sterile calendar with other biologics.
CureVac (now BioNTech)Design and manufacturingAbsorbed Dec 2025Deal was about the factory and the design stack, not a marketed shot.

mRNA Drug-Substance Footprint

Moderna, Pfizer/BioNTech, Lonza, and Thermo Fisher. Seasonal lots, not APA scale.

OperatorWhereWhat it does2026 note
ModernaUS manufacturing network (Norwood and related sites)In-house DS, LNP, fill for Spikevax, mNEXSPIKE, mRESVIA, mFLUSIVACompany is shrinking to the commercial respiratory set after pipeline cuts.
Pfizer / BioNTechPfizer Kalamazoo / Puurs; BioNTech GermanyComirnaty seasonal supplySeasonal lots, not APA scale. BioNTech added CureVac plants.
LonzaVisp and networkmRNA DS / LNP CDMOOnly name on the roster whose equity is the CDMO layer.
Thermo Fisher (Patheon)Sterile networkFill-finish more than DSDual-homed on GLP-1 because pens and vials share aseptic time.

Flu Production Technology, 2025 Sales

Sanofi mix, Seqirus adjuvanted and cell-based, GSK egg, and mRNA flu at zero 2025 sales.

Sterile Fill-Finish for Vaccines

In-house sponsors plus Thermo Fisher, Lonza, West, and Serum Institute. Shared aseptic calendar with GLP-1 pens.

PlayerRoleWhy it mattersGLP-1 overlap
PfizerIn-house vials and PFS for Prevnar, Comirnaty, AbrysvoOwns the two largest named vaccine SKUsNo
SanofiIn-house for Beyfortus, flu, PPHInfant RSV mAb is a seasonal fillNo
GSKIn-house for Shingrix, Arexvy, establishedAdjuvanted proteins, fridge chainNo
ModernaIn-house respiratorySeasonal mRNA lotsNo
Thermo Fisher (Patheon)Independent sterile networkOverflow and launch lotsYes. Dual-homed.
LonzaBiologics / mRNA fillCDMO when sponsors are fullYes. Dual-homed.
West PharmaStoppers, plungers, vial componentsEvery injectable lotYes. Dual-homed.
Serum InstituteHigh-volume vials for Gavi productsDose volume, not ASPNo

Storage Requirements by Product

Current US labels. Ultra-cold is historical for seasonal mRNA. LMIC cold chain is the remaining differentiator.

ProductPlatformLabel storagePractical point
Comirnaty / Spikevax (current seasonal)mRNAFridge for the labeled in-use windowFirst-gen -70 C is historical. US retail is a pharmacy fridge problem now.
mRESVIA / mFLUSIVAmRNAFridge, per labelSame channel as flu and COVID in season.
ShingrixAdjuvanted protein2 to 8 CTwo-vial reconstitution. Standard fridge.
Arexvy / AbrysvoProtein2 to 8 CAdult RSV is a one-and-done fridge SKU.
Gardasil 9 / PrevnarVLP / conjugate2 to 8 CPediatric and adult clinic refrigerators.
BeyfortusmAb2 to 8 CHospital and clinic, not a travel ULT story.
Gavi / SII productsMixedMostly 2 to 8 CLMIC cold chain is the remaining ULT/fridge differentiator.

Serum Institute Dose Capacity

Company-stated ~4 billion doses and 170+ countries. Volume, not a USD P&L. Gavi/UNICEF backbone.

Stated annual capacity
~4B doses
World's largest vaccine manufacturer by volume, not by revenue.
Countries reached
170+
Gavi/UNICEF backbone for pentavalent, PCV, HPV, measles.
2026 adjacency
Chikungunya
Bavarian Nordic tech-transfer (Mar 2026) for LMIC Vimkunya supply.
Not on this bar
USD P&L
Private. Compare on doses and tenders, not against Shingrix dollars.

Issuer-Filed Dose Output and Plans

GSK delivered 389 million vaccine doses in 2025. Takeda plans 21 million Qdenga doses in FY2026. Serum Institute states ~4 billion capacity. Output, plan, and capacity are not one bar.

GSK manufacturing network

Printed figure:
389 million vaccine doses delivered in 2025
What it is:
Output from 33 manufacturing sites, as printed in the 2025 annual report / 20-F
What it is not:
Not nameplate capacity. Not a like-for-like bar against Serum Institute.

GSK via Gavi

Printed figure:
99 million doses in 2025
What it is:
Output to Gavi: about 4 million Cervarix, 8 million RTS,S/AS01 malaria, 44 million Synflorix, 43 million Rotarix
What it is not:
Not the 389 million network total. Subset for lower-income countries.

GSK via UNICEF

Printed figure:
About 55 million oral polio doses in 2025
What it is:
Output through UNICEF, as printed next to the Gavi figures
What it is not:
OPV, not Sanofi IPV. Not added into the 389 million row.

Takeda Qdenga

Printed figure:
Plan to manufacture 21 million doses in FY2026
What it is:
Issuer manufacturing plan on the 13 May 2026 (updated 5 Jun 2026) FY2025 results presentation. On track toward 100 million doses per year by FY2030
What it is not:
Not 2025 actual doses. Not FY2025 sales (those were JPY 40.8B).

Serum Institute of India

Printed figure:
~4 billion dose annual capacity
What it is:
Company-stated capacity, 170+ countries. Gavi/UNICEF backbone
What it is not:
Capacity, not 2025 output. Private. Not a USD P&L.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Vaccines Supply Chain: Market Data | Sterling